Originally published as JCO Early Release 10.1200/JCO.2005.09.131 on May 2 2005
Journal of Clinical Oncology, Vol 23, No 18 (June 20), 2005: pp. 4117-4126
© 2005 American Society of Clinical Oncology.
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
P. Feugier,
A. Van Hoof,
C. Sebban,
P. Solal-Celigny,
R. Bouabdallah,
C. Fermé,
B. Christian,
E. Lepage,
H. Tilly,
F. Morschhauser,
P. Gaulard,
G. Salles,
A. Bosly,
C. Gisselbrecht,
F. Reyes,
B. Coiffier
From the Centre Hospitalier Universitaire (CHU) de Brabois, Vandoeuvre les Nancy; Centre Leon Bérard, Lyon; Centre Jean Bernard, Le Mans; Institut Paoli Calmette, Marseille; Institut Gustave Roussy, Villejuif; Hôpital Bon Secours, Metz; CHU Henri Mondor, Créteil; Centre Becquerel, Rouen; CHU de Lille, Lille; Hospices Civils de Lyon, Pierre-Bénite; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Yvoir; and Academisch Ziekenhuis Sint-Jan, Bruges, Belgium
Address reprint requests to Pierre Feugier, MD, Hematology Department, CHU de Brabois, 54500 Vandoeuvre les Nancy, France; e-mail: p.feugier{at}chu-nancy.fr
 |
ABSTRACT
|
|---|
PURPOSE: To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma.
PATIENTS AND METHODS: LNH98-5 was a randomized study that included 399 previously untreated patients, age 60 to 80 years, with diffuse large B-cell lymphoma. Patients received eight cycles of classical CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, and prednisone 40 mg/m2 for 5 days) every 3 weeks. In R-CHOP, rituximab 375 mg/m2 was administered the same day as CHOP. Survivals were analyzed using the intent-to-treat principle.
RESULTS: Median follow-up is 5 years at present. Event-free survival, progression-free survival, disease-free survival, and overall survival remain statistically significant in favor of the combination of R-CHOP (P = .00002, P < .00001, P < .00031, and P < .0073, respectively, in the log-rank test). Patients with low-risk or high-risk lymphoma according to the age-adjusted International Prognostic Index have longer survivals if treated with the combination. No long-term toxicity appeared to be associated with the R-CHOP combination.
CONCLUSION: Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up. This combination should become the standard for treating these patients.
|
INTRODUCTION
|
|---|
Diffuse large B-cell lymphoma (DLBCL) is the most frequently diagnosed non-Hodgkin's lymphoma (NHL), and more than 50% of these patients are older than 60 years. The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen has been considered the gold standard treatment for patients with DLBCL for more than 25 years. Third-generation regimens, despite their promising initial results, did not prove to be better than the standard CHOP regimen.1-3 Dose-intense CHOP-like regimens or high-dose therapy followed by autologous stem-cell transplantation (ASCT) prolong survivals in high-risk patients but these treatments have an increased toxicity in elderly patients.4,5
Rituximab (MabThera; Rituxan Roche, Neuilly-sur-Seine, France), is a chimeric human/murine immunoglobulin G1 monoclonal antibody that binds specifically to the B-cell-surface antigen, CD20. The antibody induces lymphoma cell lysis through different immunologic or direct mechanisms, complement-mediated cytolysis, antibody-dependent cell cytotoxicity, and induction of apoptosis, and acts synergistically with chemotherapy.6-9 In phase II studies, rituximab has demonstrated efficacy in DLBCL alone and in combination with the CHOP regimen (R-CHOP).10,11 In 2002, we published the first analysis of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Lymphome Non Hodgkinien study 98-5 (LNH98-5) with a 2-year follow-up showing that the addition of rituximab to CHOP chemotherapy significantly increases the rate of complete response (CR), decreases the rates of treatment failure and relapse, and improves event-free survival (EFS) and overall survival (OS) compared with standard CHOP alone in elderly patients with DLBCL.12 Because the LNH98-5 study was the first study to show a survival benefit of R-CHOP compared with CHOP chemotherapy, extended follow-up is important to determine whether the survival benefit is maintained over time and whether a definitive effect on cure rates can be shown. We report the updated results of the LNH98-5 study with a median follow-up of 5 years.
|
PATIENTS AND METHODS
|
|---|
Patients
Patients were eligible for enrollment if they were 60 to 80 years old and had previously untreated DLBCL according to the WHO classification.13 Patients were also required to have stage II, III, or IV disease and performance status 0 to 2 according to the Eastern Cooperative Oncology Group scale. Patients were excluded from the trial if they had T-cell lymphoma; a previous history of indolent lymphoma, CNS or meningeal involvement; a history of active cancer during the previous 5 years; any serious active concomitant disease; or if in the opinion of the investigator, their general status did not allow the administration of eight courses of CHOP. Patients were also excluded from the trial if they had a cardiac contraindication to doxorubicin (abnormal contractility on echocardiography), or a neurologic contraindication to vincristine. Finally, patients with positive serology for HIV or a history of unresolved hepatitis B virus infection (defined by the presence of HBs antigen or HBc antibody without HBs antibody) were not included. Patient enrollment was based on the diagnosis of DLBCL at each study center, but a panel comprising at least three hematopathologists conducted a central pathology review to confirm the diagnosis of CD20-positive DLBCL. Characteristics of the 399 patients included in this study are summarized in Table 1. 12
View this table:
[in this window]
[in a new window]
|
Table 1. Baseline Characteristics of the 399 Patients Included in the LNH98-5 Study Comparing CHOP to R-CHOP in Elderly Patients With Diffuse Large B-Cell Lymphoma
|
|
Staging comprised clinical examination, thoracic and abdominal computed tomography scans, blood counts, measurements of lactate dehydrogenase and beta2-microglobulin serum levels, bone marrow biopsy, ECG, echocardiography in patients with a history of cardiac disease or in patients older than 75 years, and CSF examination in patients with bone marrow infiltration or head and neck involvement, or if otherwise clinically indicated.
This study complied fully with all provisions of the Declaration of Helsinki and was conducted in accordance with Good Clinical Practice rules. All patients gave written informed consent to participate.
Random Assignment to Treatment
Patients were centrally randomly assigned to treatment with CHOP or R-CHOP after stratification according to center and age-adjusted International Prognostic Index (aaIPI) scores (scores 0 or 1 v 2 or 3).14
Treatment
Patients treated with CHOP received cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1.4 mg/m2 up to a maximum dose of 2 mg on day 1, with prednisone 40 mg/m2/d on days 1 to 5. Patients were treated every 3 weeks for eight cycles. Patients treated with R-CHOP received rituximab 375 mg/m2 on day 1 for each of the eight cycles. Rituximab infusion was interrupted in the event of fever, chills, edema, mucosa congestion, hypotension, or any serious adverse event, and it was resumed later. No complementary radiation therapy was scheduled either on bulky tumors or on persisting masses at the end of treatment.
If a patient developed grade 4 neutropenia or febrile neutropenia after a cycle of CHOP or R-CHOP, all subsequent cycles were administered with granulocyte colony-stimulating factor (G-CSF) support. If new grade 4 neutropenia developed with infection despite of G-CSF support, doses of cyclophosphamide and doxorubicin were decreased by 50% for all following cycles. If grade 4 neutropenia persisted, chemotherapy was discontinued. If a patient developed grade 3 or 4 thrombocytopenia, the doses of cyclophosphamide and doxorubicin were decreased by 50% for all following cycles. If grade 3 or 4 thrombocytopenia persisted, therapy was discontinued. If neutrophils were lower than 1,500/mm3 or platelets lower than 100,000/mm3 before a cycle, the cycle was delayed for up to 2 weeks. If the patient's neutrophil and platelet counts did not increase above these levels after 2 weeks, chemotherapy was discontinued. For patients receiving R-CHOP, rituximab was discontinued if CHOP was discontinued. Subsequent treatments for patients withdrawn from CHOP or R-CHOP therapy were administered at the discretion of the investigator.
Follow-Up
Response to treatment was evaluated after four and eight treatment cycles, or after the planned treatment was discontinued. Thereafter, clinical examination was performed every 3 months for the first 2 years, then every 6 months for the next 3 years, then at the discretion of the investigator. A thoracic and abdominal computed tomography scan was performed after 3 months, then every 6 months during the first 2 years, then annually for 3 more years.
Outcome Measures
The primary efficacy parameter was EFS. Events were defined as disease progression or relapse, institution of a new (unplanned) anticancer treatment, or death as a result of any cause without progression. Secondary efficacy end points included OS, progression-free survival (PFS), disease-free survival (DFS), response rates, and toxicity. The definition of PFS was almost identical to that of EFS with the exception that late deaths not related to lymphoma or its treatment were not counted as treatment failure.15 DFS only includes patients who reached a CR or undocumented CR (CRu) at the end of the treatment. EFS, PFS, and OS were calculated as the time from random assignment to the date of the first reported event. DFS was calculated as the time from response assessment to the date of the first reported event. Patients with no reported event at the time of analysis were censored at the most recent assessment date. Tumor responses were classified as CR, CRu, partial response, stable disease, or progressive disease according to the proposed International Workshop criteria.15 Survival for patients experiencing disease relapse was defined as duration from first day of the new treatment to time of death or last visit.
Statistical Analysis
Sample size was calculated on the basis of the primary end point or EFS. On the basis of various results obtained in previous studies with CHOP chemotherapy in this patient population, a conservative 3-year EFS rate of 30% was assumed for the CHOP regimen.1 To detect an increase in the 3-year EFS rate from 30% to 45%, it was calculated that 400 patients recruited during 3 years and observed for a minimum of 1 year would be required to provide 80% power at the overall 5% ( = .05, two sided) significance level. One patient was not included in the analyses because she withdrew her informed consent.
EFS, PFS, DFS, and OS were analyzed using the log-rank test and expressed as Kaplan-Meier plots. Analyses of efficacy and safety included all 399 patients randomly assigned between August 1998 and March 2000 and followed the intent-to-treat principle. Statistical analyses were performed with SAS software (SAS Institute, Cary, NC) by the GELA statistical office. All P values are two tailed.
|
RESULTS
|
|---|
Patient Characteristics and Response to Treatment
Initial characteristics of the 399 enrolled patients are summarized in Table 1. The median age of the patients at time of inclusion was 69 years. Response rates as previously published were 75% and 63% for CR and CRu, 8% and 6% for incomplete responses (partial response and stable disease), 9% and 22% for progressive disease, and 6% and 6% for death during treatment for patients treated with R-CHOP and CHOP, respectively (P = .005).12
EFS
With a median follow-up of 5 years, 248 events have been observed, 106 (52.5% of the patients) in the R-CHOP arm and 142 (72% of the patients) in the CHOP arm (Table 2). Fewer events were observed during treatment in the R-CHOP arm, as reported previously.12 Over time, more patients experienced disease relapse in the CHOP arm than in the R-CHOP arm (34% v 20%;  2 test, P < .0001). More patients died in continuous CR in the R-CHOP arm (8%) compared with the CHOP arm (2.5%; 2 test, P = .33). However, many of these patients were elderly and most of the deaths were not related to the lymphoma or its treatment but to concomitant diseases already present before the diagnosis of lymphoma or diseases that appeared subsequently, such as solid tumors. No specific pattern of causes of death was observed in these patients: three deaths were related to lymphoma treatment (Table 3), two deaths were related to severe infections, and one death was related to acute myeloid leukemia, all in R-CHOP patients. Five patients died as a result of secondary cancers (three in the CHOP arm and two in the R-CHOP arm). One and nine cardiovascular-related deaths were observed in CHOP and R-CHOP patients, respectively. At the time of analysis, 96 patients (47.5%) in the R-CHOP arm and 55 patients (28%) in the CHOP arm were in continuous CR.
The median EFS was 3.8 years (95% CI, 2.37 to not reached) in R-CHOP patients compared with 1.1 years (95% CI, 0.8 to 1.5) in CHOP patients (P = .00002; Fig 1A). The 5-year EFS was 47% (95% CI, 39.9% to 54.1%) in R-CHOP patients compared with 29% (95% CI, 23.1% to 35.8%) in CHOP patients.
View larger version (13K):
[in this window]
[in a new window]
|
Fig 1. (A) Event-free survival, (B) progression-free survival, and (C) overall survival with a median follow-up of 5 years in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and rituximab plus CHOP (R-CHOP). Log-rank test P values are = .00002, < .00001, and = .0073, respectively.
|
|
In addition, a stratified analysis according to aaIPI showed the superiority of R-CHOP over CHOP in terms of EFS in low-risk patients (5-year EFS, 63% v 34%; P = .00085) as well as in high-risk patients (41% v 27%; P = .0037; Fig 2A).
View larger version (23K):
[in this window]
[in a new window]
|
Fig 2. Event-free survival (A), progression-free survival (B), and overall survival (C) with a median follow-up of 5 years of patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab plus CHOP (R-CHOP) according to the age-adjusted International Prognostic Index score at diagnosis: (1) low-risk patients (scores 0 and 1); (2) high-risk patients (scores 2 and 3). All differences are statistically significant except for overall survival in high-risk patients: P values are .00085, .0037, .00013, .00078, .023, and .062, respectively.
|
|
PFS
PFS is a more accurate end point to describe disease-related long-term survival because it does not take into account death in continuous CR not related to lymphoma or its treatment.15 In this regard, 14 patients in the R-CHOP arm and five in the CHOP arm that were counted as having had treatment failure events in the analysis of EFS died as a result of diseases that were not related to lymphoma or its treatment (Table 3) and were censored for the PFS analysis. Median PFS was not reached (95% CI, 3.4 to not reached) for R-CHOP patients compared with 1 year (95% CI, 0.8 to 1.5) for CHOP patients (P < .00001; Fig 1B). The 5-year PFS was 54% (95% CI, 46.8% to 61.1%) in R-CHOP patients compared with 30% (95% CI, 24.4% to 37.3%) in CHOP patients. Stratified analysis according to aaIPI showed the superiority of R-CHOP over CHOP in terms of PFS in low-risk patients (5-year PFS, 69% v 34%; P = .00013) as well as in high-risk patients (47% v 29%; P = .00078; Fig 2B).
DFS
DFS analyzes the time to relapse in patients who reached a CR or CRu.15 Patients who died as a result of a non-lymphoma-related reason without disease progression were not counted as having had an event. Median DFS was not reached (95% CI, not reached to not reached) for R-CHOP patients compared with 2.45 years (95% CI, 1.49 to not reached) for CHOP patients (P = .00031). The 5-year DFS was 66% (95% CI, 56.2% to 74.0%) in R-CHOP patients compared with 45% (95% CI, 36.6% to 55.3%) in CHOP patients.
OS
Death as a result of any reason occurred in 107 patients after CHOP treatment compared with 85 patients after R-CHOP treatment, and was mostly related to lymphoma progression. Median OS was not reached (95% CI, not reached to not reached) for R-CHOP patients compared with 3.1 years (95% CI, 2.2 to not reached) for CHOP patients (P = .0073; Fig 1C). The 5-year OS was 58% (95% CI, 50.8% to 64.5%) in R-CHOP patients compared with 45% (95% CI, 39.1% to 53.3%) in CHOP patients. Stratified analysis according to aaIPI showed the significant superiority of R-CHOP over CHOP in terms of OS in low-risk patients (5-year OS, 80% v 62%; P = .023). However, the difference in high-risk patients was only of borderline significance (48% v 39%; P = .062; Fig 2C).
Progression and Salvage Therapy
Of the 399 patients, 202 (50.6%) experienced relapse or progression, including 125 (63%) in the CHOP arm and 77 (38%) in the R-CHOP arm. These patients received different salvage chemotherapy regimens according to each center policy: 14 and three patients were not treated at the time of progression in the CHOP and R-CHOP arms, respectively. Rituximab was not initially available in France and Belgium to treat DLBCL patients who experienced relapse and patients only received standard therapy. Later, rituximab was registered and became available to treat DLBCL: as a result, 22 (20%) of the 109 treated patients in the CHOP arm and nine (12%) of 73 in the R-CHOP arm received rituximab-containing salvage chemotherapy. This explained a difference between the group of patients treated with or without rituximab plus chemotherapy at time of relapse: patients treated without rituximab had a significantly shorter duration of response to CHOP/R-CHOP (P < .01). Otherwise the clinical characteristics and response to initial treatment were comparable in both groups. Salvage chemotherapy regimens were mainly dexamethasone, cisplatin, and cytarabine; etoposide, cytarabine, cisplatin, and methylprednisolone; or ifosfamide, carboplatin, and etoposide regimens. Only one patient received autologous transplantation after salvage therapy.
The 2-year survival rates of re-treated patients were not statistically different for the two initial randomization arms (26% and 31% in R-CHOP and CHOP arms, respectively; P = .83). However, there was a statistically significant difference for survival if patients received a salvage regimen containing rituximab or not: patients treated with a rituximab-containing regimen had a 2-year survival of 58% compared with 24% for those treated without rituximab (log-rank test, P = .00067; data not shown). Figure 3 shows the survival of these patients according to the randomization groups (CHOP and R-CHOP) and to salvage regimens (with or without rituximab). In the CHOP arm, the benefit of the addition of rituximab at time of salvage therapy is statistically significant (log-rank test, P = .002), whereas it is not statistically significant in the R-CHOP arm (log-rank test, P = .23). However, only nine patients received a second regimen with rituximab in the R-CHOP arm. If we only analyzed the 64 patients with duration of response to CHOP/R-CHOP longer than 1 year, patients treated with rituximab have a statistically significantly longer survival than patients treated without rituximab at time of relapse (P = .016; median survival not reached compared with 1 year, respectively). Patients who were refractory to chemotherapy (response to CHOP/R-CHOP less than 1 year) did not show a difference in survival according to salvage treatment.
View larger version (9K):
[in this window]
[in a new window]
|
Fig 3. Effect of rituximab-containing chemotherapy as salvage treatment at time of first progression on overall survival after progression: (A) in patients previously treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; log-rank test, P = .00043); (B) in patients previously treated with rituximab plus CHOP (log-rank test, P = .076).
|
|
Toxicity
As previously reported, rituximab did not add toxicity to the CHOP regimen.12 There was a trend to increased occurrence of infections in all R-CHOP patients after the end of treatment (12 in R-CHOP v six in the CHOP group). Deaths without disease progression were more frequent in R-CHOP patients. No specific pattern of causes of death was observed (Table 3).
Nineteen patients have presented a second tumor, 10 in the CHOP group and nine in the R-CHOP group. Two of them might be considered related to treatment: one myelodysplastic syndrome in a CHOP patient and one acute myeloid leukemia in an R-CHOP patient. No pattern was observed for solid tumors, with five lung; three renal; two melanoma and colon; and one each ovarian, prostate, head and neck, cutaneous, and breast cancers.
|
DISCUSSION
|
|---|
In this update, we report the long-term results of the first randomized trial with rituximab in combination with chemotherapy in lymphoma, the results of which were published previously with a median follow-up of 2 years.12 The updated analysis with a median 5-year follow-up confirmed previous results showing a significant prolongation of EFS, PFS, DFS, and OS for patients treated with R-CHOP compared with those treated with CHOP alone. The longer survivals observed in the R-CHOP group is due to lower rates of disease progression during therapy and lower rates of relapse after reaching a CR. Importantly, the EFS, PFS, DFS, and OS curves for R-CHOP and CHOP alone remained separated throughout the follow-up period, indicating that the benefit of combining rituximab with CHOP is durable and translates into an increase in the number of patients who are cured of their lymphoma. After a median follow-up of 5 years, 26% more patients were alive in the R-CHOP arm than in the CHOP arm.
Subgroup analysis showed superior EFS and PFS in patients with both high- and low-risk aaIPI scores. However, we observed a statistically significant superiority of OS only in low-risk aaIPI patients but not in high-risk aaIPI patients, mainly due to a higher mortality rate in high-risk patients from diseases unrelated to lymphoma. As our patients became older, we observed more deaths in CR, particularly in patients treated with R-CHOP, even if there was not a statistically significant difference between the two arms. Most of the CHOP patients died after disease progression, whereas R-CHOP patients did not experience disease relapse. As a logical consequence, patients in the latter group died from other, non-lymphoma-related diseases. We observed that patients with concomitant diseases or those with poor performance status at the time of diagnosis are more prone to die in CR, a fact that is also observed in the general population. We do not believe that this is related to the treatment received by our patients but rather to the fact that our patients followed a typical natural life history.
Since the first publication of our results, several randomized studies testing the addition of rituximab to chemotherapy in different settings have been presented. The Intergroup study (Eastern Cooperative Oncology Group 4494) was more complicated to analyze because of a double randomization, initially between CHOP and R-CHOP, and secondarily for responding patients between no additional treatment and a maintenance treatment with rituximab for 2 years.16 These patients received half of the rituximab dose administered in our study. Patients treated with R-CHOP seemed to do better than those treated with CHOP only, and rituximab maintenance was mainly effective in patients who did not receive rituximab previously. These results might be interpreted as consistent with our findings but a longer follow-up is certainly necessary to draw any final conclusion. Sehn et al17 reported a Canadian population-based retrospective analysis comparing outcomes of 294 DLBCL patients treated with a CHOP-like regimen or R-CHOP-like regimen. Dose and schedule of rituximab administration were similar to the LNH98-5 study. With a median 2-year follow-up, the authors showed that the addition of rituximab to CHOP has resulted in a dramatic improvement in outcome, both in young and elderly patients. Finally, the MabThera International Trial study showed a similar benefit for the combination of rituximab and CHOP-like chemotherapy in young patients with low- and low-intermediate-risk DLBCL.18 Other studies have been conducted in patients with follicular lymphoma or mantle-cell lymphoma and showed the same benefit for the combination of rituximab plus chemotherapy.19,20 These data represent a real breakthrough in the treatment of lymphoma patients and suggest that R-CHOP should become the new standard treatment for patients with DLBCL.
Adverse events were not increased in patients treated with the combination of rituximab plus chemotherapy compared with chemotherapy alone, suggesting that rituximab is well tolerated. Other studies recently published have confirmed this low toxicity. We did not observe any difference between the incidence of secondary hematologic and nonhematologic cancers in the two regimens. Life-threatening or fatal cardiac events were also similar in both arms of the study.
High-dose therapy followed by ASCT is the treatment of choice for patients with relapsed DLBCL who are still responding to salvage therapy.21,22 However, elderly patients are usually not candidates for ASCT because of age and comorbidity, and a regimen that is easily tolerated yet provides a reasonable response rate may be an attractive alternative to more toxic regimens. Rituximab has been shown to be active both as a single agent and in combination with chemotherapy in relapsed or resistant DLBCL.10,23,24 An early phase II study evaluating the combination of rituximab with the etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen in 50 heavily pretreated patients showed a response rate of 64%.25 The EFS and OS at 2 years was 36% and 52%, respectively, with a median EFS and OS of 14 and 29 months, respectively. Our study provides the opportunity to evaluate the rituximab efficacy in patients experiencing relapse who did or did not receive rituximab previously. Although it was not a randomized study, our results support the idea that combined chemotherapy plus rituximab could improve OS when compared with chemotherapy alone in this setting. However, because of the low number of patients re-treated with rituximab, we cannot make a definitive conclusion regarding these patients.
Future studies should focus on decreasing the relapse rate without increasing toxicity in these elderly patients. Rituximab administered as maintenance therapy in patients with CR might decrease the relapse rate by increasing the quality of the response. This modality certainly should be tested in a study designed specifically to answer this question, even if the preliminary results of the Intergroup study seem to invalidate this hypothesis. Although difficult to perform in elderly patients, dose intensification of the CHOP regimen by increasing doses or shortening the administration schedule with G-CSF support could be another way to increase the CR rate and to decrease the relapse rate.5,26,27
|
Appendix
|
|---|
The following persons and institutions participated in this GELA study: Pathologic review committee—J. Brière, P. Gaulard, J. Bosq, J.F. Emile, B. Fabiani, and T. Petrella; Statistics—E. Lepage and N. Nio; Pharmacist—I. Madelaine; GELA clinical research—M. Fiore, K. Privat, E. Capellani and all CRA who collected the data; study centers (all in France, unless otherwise specified)—Centre Hospitalier Lyon-Sud, Pierre-Bénite—B. Coiffier, G. Salles, C. Traullé and C. Thieblemont; Hôpital de Hautepierre, Strasbourg—R. Herbrecht; Centre Becquerel, Rouen—H. Tilly; Centre Jean Bernard, Le Mans—P. Solal-Celigny; Institut Paoli Calmette, Marseilles—R. Bouabdallah; Centre Hospitalier Universitaire de Brabois, Nancy—P. Lederlin, P. Feugier; Centre Léon Bérard, Lyon—C. Sebban; Institut Gustave Roussy, Villejuif—J.N. Munck, C. Fermé; Centre Hospitalier de Lens, Lens—P. Morel; Hôpital Henri Mondor, Creteil—F. Reyes, C. Haioun; Centre Hospitalier de Chambéry, Chambéry—M. Blanc; Hôpital Bon Secours, Metz—B. Christian; Centre Hospitalier Universitaire de Lille, Lille—B. Quesnel; Academisch Ziekenhuis Sint-Jan, Bruges, Belgium—A. Van Hoof; Hôpital Saint-Louis, Paris—C. Gisselbrecht, N Mounier, P. Brice; Hôpital Purpan, Toulouse—M. Attal; Centre Hospitalier Universitaire Dupuytren, Limoges—D. Bordessoule; Hôpital Jean Bernard, Poitiers—V. Delwail; Université Catholique de Louvain, Yvoir, Belgium—A. Bosly; Centre Hospitalier Universitaire Clemenceau, Caen—M. Macro; Centre François Magendie, Pessac—G. Marit; Hôpital Pitié Salpétrière, Paris—J. Gabarre; Hôpital André Mignot, Le Chesnay—S. Castaigne; Centre Hospitalier Universitaire de Nîmes, Nîmes—E. Jourdan; Centre Hospitalier de la Durance, Avignon—E. Lepeu; Hôpital Pasteur, Colmar—B. Audhuy; Centre Antoine Lacassagne, Nice—A. Thyss; Clinique Pasteur, Evreux—N. Albin; Centre Médical Foch, Suresnes—E. Baumelou; Hôtel Dieu, Paris—A. Delmer; Centre Hospitalier de Brive, Brive—S. Lefort; Centre Hospitalier de Bourg en Bresse, Bourg en Bresse—H. Orfeuvre; Hôpital V. Prouvo, Roubaix—I. Plantier; Hôpital Bicêtre, Le Kremlin-Bicêtre—G. Tertian; Hôpital Necker, Paris—B. Varet; Hôpital Beclere, Clamart—F. Boué; Centre Hospitalier Universitaire de Dijon, Dijon—O. Casasnovas and D. Caillot; Université Catholique de Louvain, Brussels, Belgium—E. Van Den Neste; Institut Curie, Paris—D. Decaudin; Centre Hospitalier Universitaire Saint-Louis-Lariboisière, Paris—H. Dombret, J.P. Fermand, and J.M. Zini; Centre Hospitalier Universitaire de Liège, Liège, Belgium—G. Fillet; Fondation Drevon, Dijon—M. Flesch; Centre Hospitalier R. Dubos, Pontoise—Y. Kerneis; Centre Hospitalier d'Annecy, Annecy—C. Martin; Hôpital de Valence, Valence—P.Y. Péaud; Centre Hospitalier de Blois, Blois—P. Rodon; Centre Hospitalier Saint-Vincent, Lille—C. Rose; Hôtel Dieu, Clermont-Ferrand—P. Travade; Clinique Saint-Jean, Lyon—B. Velay; Hôpital de Bayonne, Bayonne—F. Bauduer; Centre Hospitalier de Libourne, Libourne—K. Bouabdallah; Hôpital Emile Muller, Mulhouse—J.C. Eisenmann; Hôpital Marc Jacquet, Melun—C. Kulekci; Centre Hospitalier Bois de l'Abbaye, Seraing, Belgium—S. Lampertz; Hôpital Inter Armées Percy, Clamart—G. Nedellec; Centre François Baclesse, Caen—A.M. Peny; Centre Hospitalier Victor Dupouy, Argenteuil—V. Pulik; Hôpital de Chalon, Chalon—B. Salles; Centre Hospitalier de Perpignan, Perpignan—X. Vallantin; Centre Hospitalier Robert Ballanger, Aulnay sous Bois—P. Agranat; Centre Hospitalier Universitaire de Nice, Nice—J.P. Cassuto; Centre Hospitalier Hutois, Huy, Belgium—J. Collignon; Centre Hospitalier de la Citadelle, Liège, Belgium—B. de Prijck; Hôpital Jolimont, Haine Saint Paul, Belgium—A. Delannoy; Centre Hospitalier Gilles de Corbeil, Corbeil Essonnes—A. Devidas; Hôpital La Fontonne, Antibes—J.F. Dor; Hôpital Cochin, Paris—F. Dreyfus; Clinique Saint Jean, Brussels, Belgium—C. Dubois; Clinique de Chaumont, Chaumont—G. Dupont; Centre Val d'Aurelle, Montpellier—M. Fabbro; Hôpital J. Monod, Le Havre—C. Fruchart; Clinique les Fougères, Dieppe—J.P. Gaillard; Centre Hospitalier Universitaire de Rennes, Rennes—B. Grosbois; Centre René Huguenin, Saint-Cloud—M. Janvier; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland—N. Ketterer; Centre Hospitalier du Val de Sambre, Sambreville, Belgium—C. Leroy; Clinique Saint Pierre, Ottignies, Belgium—M. Maerevoet; Hôpital des Canaux, Macon—F. Marechal; Hôpital Saint Joseph, Gilly, Belgium—P. Mineur; Hôpital Saint Joseph, Arlon, Belgium—P. Pierre; Centre Hospitalier Universitaire Nord, Marseille—G. Sebahoun; and Centre Hospitalier de Meaux, Meaux—C. Soussain.
|
Authors' Disclosures of Potential Conflicts of Interest
|
|---|
The following authors or their immediate family members have indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. Consultant/Advisory Role: P. Solal-Celigny, Roche; A. Bosly, Roche; C. Gisselbrecht, Baxter, Roche, Schering; B. Coiffier, Genentech, Roche. Honoraria: P. Solal-Celigny, Produits Roche; H. Tilly, Roche; G. Salles, Roche; C. Gisselbrecht, Roche; F. Reyes, Roche; B. Coiffier, Genentech, Roche. Research Funding: A. Bosly, Roche; B. Coiffier, Genentech. For a detailed description of these categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and Disclosures of Potential Conflicts of Interest found in Information for Contributors in the front of each issue.
|
NOTES
|
|---|
Authors' disclosures of potential conflicts of interest are found at the end of this article.
|
REFERENCES
|
|---|
1. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993[Abstract/Free Full Text]
2. Coiffier B: Increasing chemotherapy intensity in aggressive lymphomas: A renewal? J Clin Oncol 21:2457-2459, 2003[Free Full Text]
3. Coiffier B: Treatment of aggressive lymphomas, disseminated cases, in Perry MC (ed): 2003 ASCO Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2003, pp 606-611
4. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol—A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 18:3025-3030, 2000[Abstract/Free Full Text]
5. Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003[Abstract/Free Full Text]
6. Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104:2635-2642, 2004[Abstract/Free Full Text]
7. Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738-2743, 2004[Abstract/Free Full Text]
8. Eisenbeis CF, Caligiuri MA, Byrd JC: Rituximab: Converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res 9:5810-5812, 2003[Free Full Text]
9. Smith MR: Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22:7359-7368, 2003[CrossRef][Medline]
10. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998[Abstract/Free Full Text]
11. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001[Abstract/Free Full Text]
12. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002[Abstract/Free Full Text]
13. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France, International Agency for Research on Cancer, 2001
14. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993[Abstract/Free Full Text]
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999[Abstract/Free Full Text]
16. Habermann TM, Weller EA, Morrison VA, et al: Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 102:6a, 2003 (suppl 1)
17. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). Blood 102:29a, 2003 (suppl 1)
18. Pfreundschuh MG, Trümper L, Ma D, et al: Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab: Early stopping after the first interim analysis. Proc Am Soc Clin Oncol 23:556, 2004 (abstr 6500)
19. Dreyling MH, Forstpointner R, Repp R, et al: Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102:103a, 2003 (suppl 1; abstr 351)
20. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005[Abstract/Free Full Text]
21. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995[Abstract/Free Full Text]
22. Shipp MA, Abeloff MD, Antman KH, et al: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. J Clin Oncol 17:423-429, 1999[Free Full Text]
23. Coiffier B: Chemotherapy combined with monoclonal antibodies in the treatment of patients with diffuse large B-cell lymphoma, in DeVita VT, Hellman S, Rosenberg SA (eds): Progress in Oncology 2004. Sudbury, MA, Jones & Bartlett, 2005, pp 220-235
24. Coiffier B: Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 31:7-11, 2004[CrossRef][Medline]
25. Wilson WH, Gutierrez M, O'Connor P, et al: The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47, 2002
26. Coiffier B: Dose intensity or monoclonal antibody in first-line treatment. Hematol J 5:S154-S158, 2004 (suppl 3)
27. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004[Abstract/Free Full Text]
Submitted September 29, 2004;
accepted February 10, 2005.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Copie-Bergman, P. Gaulard, K. Leroy, J. Briere, M. Baia, J.-P. Jais, G. A. Salles, F. Berger, C. Haioun, H. Tilly, et al.
Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
J. Clin. Oncol.,
November 20, 2009;
27(33):
5573 - 5579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. White, A. P. DeHaan, J. M. Wilson, M. H. Zakem, and T. J. Maatman
Synchronous Advanced Pure Seminoma and Diffuse Large B-Cell Lymphoma: A Case of Multiple Oncologic Dilemmas
J. Clin. Oncol.,
November 10, 2009;
27(32):
e181 - e183.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Gundrum, M. A. Mathiason, D. B. Moore, and R. S. Go
Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab
J. Clin. Oncol.,
November 1, 2009;
27(31):
5227 - 5232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Villa, J. M. Connors, T. N. Shenkier, R. D. Gascoyne, L. H. Sehn, and K. J. Savage
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
Ann. Onc.,
October 27, 2009;
(2009)
mdp432v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gisselbrecht, J. Vose, A. Nademanee, A. M. Gianni, and A. Nagler
Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response
Oncologist,
October 1, 2009;
14(suppl_2):
41 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Al Zahrani, N. Ibrahim, and A. Al Eid
Rapid Infusion Rituximab Changing Practice for Patient Care
Journal of Oncology Pharmacy Practice,
September 1, 2009;
15(3):
183 - 186.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood,
May 14, 2009;
113(20):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and M. J. Rummel
Bendamustine: Rebirth of an Old Drug
J. Clin. Oncol.,
March 20, 2009;
27(9):
1492 - 1501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin
A Look in the Mirror
J. Clin. Oncol.,
March 10, 2009;
27(8):
1158 - 1159.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grange, E. Maubec, M. Bagot, M. Beylot-Barry, P. Joly, S. Dalle, E. Delaporte, O. Dereure, H. Bachelez, B. Vergier, et al.
Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab
Arch Dermatol,
March 1, 2009;
145(3):
329 - 330.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al.
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
Ann. Onc.,
March 1, 2009;
20(3):
503 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Zhao, A. Auerbach, A. M. D'Costa, A. P. Rapoport, A. M. Burger, E. A. Sausville, S. A. Stass, F. Jiang, A. M. Sands, N. Aguilera, et al.
Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy
Clin. Cancer Res.,
March 1, 2009;
15(5):
1708 - 1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Lee, C. A. Green, O. G. Negrea, S. Dodson, S. K. Farrell, J. E. Hewitt, T. Jago, C. E. Ramsey, T. Cato, E. Crawford, et al.
B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP
Lab Med,
February 1, 2009;
40(2):
79 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol,
January 1, 2009;
11(5):
503 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Psyrri, S. Papageorgiou, and T. Economopoulos
Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management
Ann. Onc.,
December 1, 2008;
19(12):
1992 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Wiernik, I. S. Lossos, J. M. Tuscano, G. Justice, J. M. Vose, C. E. Cole, W. Lam, K. McBride, K. Wride, D. Pietronigro, et al.
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
October 20, 2008;
26(30):
4952 - 4957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
October 1, 2008;
26(28):
4587 - 4594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al.
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Blood,
September 15, 2008;
112(6):
2248 - 2260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al.
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
J. Clin. Oncol.,
June 1, 2008;
26(16):
2717 - 2724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Crump, B. Coiffier, E. D. Jacobsen, L. Sun, J. L. Ricker, H. Xie, S. R. Frankel, S. S. Randolph, and B. D. Cheson
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Ann. Onc.,
May 1, 2008;
19(5):
964 - 969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jaeger, F. Bauer, R. Brezinschek, C. Beham-Schmid, C. Mannhalter, and P. Neumeister
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine
Ann. Onc.,
May 1, 2008;
19(5):
1025 - 1026.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, et al.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
Ann. Onc.,
April 1, 2008;
19(4):
769 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Vellenga, W. L. J. van Putten, M. B. van 't Veer, J. M. Zijlstra, W. E. Fibbe, M. H. J. van Oers, L. F. Verdonck, P. W. Wijermans, G. W. van Imhoff, P. J. Lugtenburg, et al.
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
Blood,
January 15, 2008;
111(2):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Krishnan, A. Nademanee, H. C. Fung, A. A. Raubitschek, A. Molina, D. Yamauchi, R. Rodriguez, R. T. Spielberger, P. Falk, J. M. Palmer, et al.
Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 1, 2008;
26(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood,
January 1, 2008;
111(1):
369 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Blood,
October 1, 2007;
110(7):
2569 - 2577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fillet and C. Bonnet
In Reply
J. Clin. Oncol.,
July 1, 2007;
25(19):
2857 - 2858.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar
FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Haematologica,
July 1, 2007;
92(7):
998 - 999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood,
July 1, 2007;
110(1):
29 - 36.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, T. Illidge, D. Huglo, G. Martinelli, G. Paganelli, P. L. Zinzani, S. Rule, A. M. Liberati, N. Milpied, G. Hess, et al.
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
Blood,
July 1, 2007;
110(1):
54 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, L. Balducci, and M. Aapro
Geriatric Oncology: A Field Coming of Age
J. Clin. Oncol.,
May 10, 2007;
25(14):
1821 - 1823.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol.,
May 10, 2007;
25(14):
1832 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Terret, G. B. Zulian, A. Naiem, and G. Albrand
Multidisciplinary Approach to the Geriatric Oncology Patient
J. Clin. Oncol.,
May 10, 2007;
25(14):
1876 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Thieblemont and B. Coiffier
Lymphoma in Older Patients
J. Clin. Oncol.,
May 10, 2007;
25(14):
1916 - 1923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al.
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
May 2, 2007;
99(9):
706 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc.,
May 1, 2007;
18(5):
931 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bonnet, G. Fillet, N. Mounier, G. Ganem, T. J. Molina, C. Thieblemont, C. Ferme, B. Quesnel, C. Martin, C. Gisselbrecht, et al.
CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol.,
March 1, 2007;
25(7):
787 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Blood,
March 1, 2007;
109(5):
1857 - 1861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Dunleavy, R. E. Davis, O. Landgren, L. M. Staudt, and W. H. Wilson
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
Blood,
January 15, 2007;
109(2):
843 - 844.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Arnold, F. Dentali, M. A. Crowther, R. M. Meyer, R. J. Cook, C. Sigouin, G. A. Fraser, W. Lim, and J. G. Kelton
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
Ann Intern Med,
January 2, 2007;
146(1):
25 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann
Antibody Therapy in Aggressive Lymphomas
Hematology,
January 1, 2007;
2007(1):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Forstpointner, M. Unterhalt, M. Dreyling, H.-P. Bock, R. Repp, H. Wandt, C. Pott, J. F. Seymour, B. Metzner, A. Hanel, et al.
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Blood,
December 15, 2006;
108(13):
4003 - 4008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Kim, H. D. Jung, J. G. Kim, J.-J. Lee, D.-H. Yang, Y. H. Park, Y. R. Do, H. J. Shin, M. K. Kim, M. S. Hyun, et al.
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Blood,
October 15, 2006;
108(8):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
Blood,
October 15, 2006;
108(8):
2874 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Betticher, G Martinelli, J. Radford, M Kaufmann, M. Dyer, U Kaiser, W. Aulitzky, J Beck, A von Rohr, T Kovascovics, et al.
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
Ann. Onc.,
October 1, 2006;
17(10):
1546 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, E. A. Weller, V. A. Morrison, R. D. Gascoyne, P. A. Cassileth, J. B. Cohn, S. R. Dakhil, B. Woda, R. I. Fisher, B. A. Peterson, et al.
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
July 1, 2006;
24(19):
3121 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Stewart, N. Bahlis, K. Valentine, A. Balogh, L. Savoie, D. G. Morris, A. Jones, C. Brown, and J. A. Russell
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma
Blood,
June 15, 2006;
107(12):
4623 - 4627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Provencio, S. Cerdeira, F. Bonilla, A. Sanchez, and P. Espana
Rapid-infusion rituximab in lymphoma treatment
Ann. Onc.,
June 1, 2006;
17(6):
1027 - 1028.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Tsimberidou, S. O'Brien, I. Khouri, F. J. Giles, H. M. Kantarjian, R. Champlin, S. Wen, K.-A. Do, S. C. Smith, S. Lerner, et al.
Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation
J. Clin. Oncol.,
May 20, 2006;
24(15):
2343 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zuckerman, R. Seliem, and E. Hochberg
Intravascular Lymphoma: The Oncologist's "Great Imitator".
Oncologist,
May 1, 2006;
11(5):
496 - 502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kober, H. Hulsewede, J. Bohlius, and A. Engert
Fourth biannual report of the Cochrane Haematological Malignancies Group.
J Natl Cancer Inst,
April 19, 2006;
98(8):
E1 - E1.
[Full Text]
|
|
|
|
|
|
|
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Dunleavy, W. H. Wilson, and L. D. Kaplan
The case for rituximab in AIDS-related lymphoma.
Blood,
April 1, 2006;
107(7):
3014 - 3015.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Coiffier
State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6387 - 6393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson and M. A. Shipp
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Blood,
August 15, 2005;
106(4):
1164 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell and J. Armitage
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1087 - 1097.
[Abstract]
[PDF]
|
|
|
|
TOP
ABSTRACT
INTRODUCTION
